Chico, Calif., November 5, 2012 – NuvoLase Inc. announced today more then 100,000 procedures have now been performed with the PinPointe FootLaser worldwide, more than many of the other light-based options combined.
The PinPointe FootLaser was the first light-based device to receive FDA clearance to treat onychomycosis (commonly known as nail fungus), and remains one of the only devices on the market today with documented clinically proven efficacy. The PinPointe FootLaser has been found to be an effective alternative to oral medications, which can be risky for the patient. The PinPointe FootLaser has been cleared by the FDA for the temporary improvement in the appearance of clear nail in patients with onychomycosis.
“This is very exciting and an important milestone for NuvoLase and the PinPointe FootLaser.”
“This is very exciting and an important milestone for NuvoLase and the PinPointe FootLaser,” says Steven P. Duddy, President and Chief Executive Officer of NuvoLase Inc. “The PinPointe FootLaser remains the light-based procedure of choice by many clinicians and patients worldwide, and surpassing the 100K procedure mark shows that we are gaining momentum as the acknowledged procedure of choice for onychomycosis.”
Dr. Dan Waldman DPM, Board Certified Foot Surgeon located in North Carolina states, “We have performed thousands of procedures with the PinPointe FootLaser and our patients have been extremely satisfied with the results – they also report that the FootLaser has no side effects, which is important.” He adds, “This breakthrough technology has changed the way we approach patients suffering from unsightly nail fungus and has changed the lives of many of our patients.”
The PinPointe FootLaser is available worldwide, and currently holds approvals including FDA clearances, CE Mark, TGA, and MHLW approval in Japan and Health Canada.
“We’re working to expand to as many markets as possible, both domestically and abroad,” Duddy explains. “We want people all over the world to be able to get the effective treatment that over 100,000 patients have already enjoyed.”
About NuvoLase Inc.
NuvoLase, Inc. develops and markets innovative devices for healthcare providers worldwide. NuvoLase products are the result of solid research, sound science, and extensive clinical experience, ensuring that they always provide superior clinical performance. The PinPointe FootLaser is available worldwide. For more information about laser for toe fungus, visit our website at www.nuvolase.com.
NuvoLase, PinPointe, and PinPointe FootLaser are trademarks of NuvoLase, Inc.
NuvoLase Inc.
11 Ilahee Lane
Chico, CA 95973
530-809-1970
Patients seeking additional information on Treatments for Onychomycosis or a doctor in their area who offers the PinPointe FootLaser procedure can call 1-877-ToeNail (1-877-863-6245) or visitwww.PinPointeFootLaser.com/patients/find-a-provider.
Clinicians interested in learning more about the PinPointe FootLaser or interested in purchasing one for their business can contact NuvoLase’s distribution partner, Cynosure Inc., directly at 800-886-2966 or visit their website at www.cynosure.com.
Contact:
Steven P. Duddy
Phone: 530.809.1970 ext 207
Fax: 866.235.1386
sduddy@nuvolase.com
Click Here to view original Press Release.
